Diseases [C] » Neoplasms [C04] » Hamartoma
Description
A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area. MeSH
Hierarchy View
Subtype Terms (3)
Hamartoma Syndrome, Multiple
6 drugs (3 approved, 3 experimental)
Tuberous Sclerosis
13 drugs (10 approved, 3 experimental)
Phase 4 Indicated Drugs (16)
Phase 3 Indicated Drugs (46)
Phase 2 Indicated Drugs (162)
allogeneic natural killer cells
autologous hematopoietic stem cells
modified vaccinia ankara-5t4 vaccine
modified vaccinia virus ankara vaccine expressing p53
n-(4-hydroxyphenyl)all-trans retinamide
oncolytic measles virus encoding thyroidal sodium iodide symporter
peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1
recombinant adenoviral human p53 gene
Phase 1 Indicated Drugs (85)
autologous ny-eso-1-specific cd8-positive t lymphocytes
ex vivo cd3/cd28-costimulated vaccine-primed peripheral blood autologous t cells
genetically engineered ny-eso-1-specific t lymphocytes
globo-h-gm2-stn-tf-tn-klh conjugate
her2bi-armed activated t cells
Other Experimental Indicated Drugs (17)
Organization Involved with Phase 2 Indications (8)
Organization Involved with Other Experimental Indications (1)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
